Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Breast Cancer Research : BCR|January 10, 2016
Increased peri-ductal collagen micro-organization may contribute to raised mammographic densityJames C McConnell, Oliver V O'Connell, Keith Brennan, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 12, 2022
The MARECA (national study of management of breast cancer locoregional recurrence and oncological outcomes) study: National practice questionnaire of United Kingdom multi-disciplinary decision makingJenna L Morgan, Vinton Cheng, Peter A Barry, et al.
International Journal of Surgery Protocols|August 25, 2020
The B-MaP-C study: Breast cancer management pathways during the COVID-19 pandemic. Study protocolAlona Courtney, Rachel O'Connell, Tim Rattay, et al.
International Journal of Surgery Protocols|March 4, 2024
The MARECA (national study of management of breast cancer locoregional recurrence and oncological outcomes) study: protocol for a prospective, multicentre cohort studySue M Hartup, Jenna L Morgan, Vinton Wt Cheng, et al.
Breast Cancer Research and Treatment|April 3, 2023
Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C studyRajiv V Dave, Beatrix Elsberger, Vicky P Taxiarchi, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 23, 2026
National United Kingdom study of the management of breast cancer locoregional recurrence (MARECA) study: Analysis of disease presentation and patient managementJenna L Morgan, Thomas Hubbard, Esther Herbert, et al.
British Journal of Cancer|March 26, 2021
Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C studyRajiv V Dave, Baek Kim, Alona Courtney, et al.
Health Technology Assessment (Winchester, England)|November 22, 2023
One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCTAdrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, et al.
Lancet (London, England)|June 26, 2020
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trialAdrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, et al.
The Lancet. Oncology|May 14, 2026
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudyAdrian Murray Brunt, Fay H Cafferty, Anna M Kirby, et al.
Pageof 9